Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), a biotech company with a market capitalization of $427 million and currently trading at $24.39, recently reported that Dean Schorno, the company's Executive ...
Rigel Resource Acquisition Corp (RRAC) recently announced the postponement of its extraordinary general meeting scheduled for February 13, 2025. The meeting has been rescheduled to February 28, 2025, ...
Hattiesburg-Laurel WDAM-TV on MSN3d
'It's not like the cartoons': Practicing gun safety around kidsAn uptick in accidental shootings involving children has some in law enforcement speaking out.Lamar County Sheriff Danny ...
Singapore-based Rigel Capital is set to announce the final close of its first early-stage fund, Rigel Star, at slightly over $40 million soon, pushing the total capital the firm has raised across its ...
Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety ...
Rigel will mail the definitive proxy statement/prospectus to shareholders of record as of the close of business on January 10, 2025. Rigel will hold its Extraordinary General Meeting (the ...
In the press release titled “Rigel Provides Business Update and 2025 Outlook,” Rigel Pharmaceuticals shared some significant financial highlights. For the fourth quarter of 2024, the company ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback